Lung Therapeutics Raises $14.3 Million to Develop Treatments for Pulmonary Fibrosis, Other Diseases

Lung Therapeutics Raises $14.3 Million to Develop Treatments for Pulmonary Fibrosis, Other Diseases

Lung Therapeutics announced June 6 that it has completed a $14.3 million Series B financing round to support development of LTI-03, its lead therapy for idiopathic pulmonary fibrosis (IPF). LTI-03 has already showed promising results for other conditions including scleroderma and cardiac fibrosis. The funds will also support clinical trials, now underway in Australia and…

The Economic Impact of Lung Disease

Lung disease has a deep impact in Canada. Lung cancer remains the leading cause of death from cancer for both genders and each year more people die of lung cancer than those of prostate cancer, breast cancer, and colorectal cancer combined. MORE:…

7 Common Symptoms of Pulmonary Fibrosis

Pulmonary fibrosis is a progressive chronic lung disease where the tissue in the lungs becomes thick and stiff, making it increasingly difficult to breathe and leading to a low level of oxygen in the blood. In the early stages of the disease, the symptoms can mimic many other illnesses which…